This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Abeona Therapeutics, Inc.
Drug Names(s): Polymer Platinate, AP5346
Description: ProLindac is a prodrug of DACH platinum in which the cytotoxic agent is bound to a water-soluble biocompatible copolymer backbone called hydroxypropylmethacrylamide (HPMA). In ProLindac, platinum is believed to be released by a mechanism which makes use of the fact that tumors are generally more acidic than surrounding normal tissue. ProLindac releases platinum much more rapidly in a slightly acidic environment compared with an environment at physiological pH.
Deal Structure: JCOM Co., Ltd., is the Korean licensee for ProLindac.
Jiangsu Aosaikang Pharmaceutical Co., Ltd, is the Chinese licensee for ProLindac.
Additional information available to subscribers only: